Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
7:44pm GMT
Change (% chg)

$-0.02 (-0.48%)
Prev Close
$4.17
Open
$4.14
Day's High
$4.18
Day's Low
$4.14
Volume
2,662
Avg. Vol
6,305
52-wk High
$11.65
52-wk Low
$3.15

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $32.35
Shares Outstanding(Mil.): 8.91
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -2.78 -- --
ROI: -47.46 8.92 14.45
ROE: -70.71 10.08 15.96

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

22 Oct 2018

Earnings vs. Estimates